

Urteste S.A.
ul. Starodworska 1
80-137 Gdańsk

November 21, 2024

**Current report No. 14/2024
of 21.11.2024**

Subject: Signing of a funding agreement with the Polish Agency for Enterprise Development.

Legal Basis: Article 17(1) of MAR - Confidential Information

The Management Board of Urteste S.A., based in Gdańsk (the "Issuer" or the "Company"), refers to Current Report No. 9/2024 of September 20, 2024, and informs that on November 21, 2024, an agreement was signed between the Company and the Polish Agency for Enterprise Development (PARP) regarding the implementation and co-financing of a project entitled: *"NASTRO Test - an enzymatic, low-cost IVD test for the early-stage diagnosis of breast cancer, international protection of intellectual property rights for a new diagnostic breast marker, and the acquisition and development of competencies of the Urteste S.A. Team in R&D and commercialization"* (the "Project").

The total net value of the Project is PLN 20,820,182.52, and the recommended funding amount indicated in the PARP list is PLN 11,499,611.95.

The Project implementation period and eligible expenses began on January 2, 2024, and will conclude on December 31, 2029.

The project's objective is to develop an innovative diagnostic test that detects early-stage breast cancer based on substrates reacting with the urine of patients with specific cancer types and to evaluate the test's clinical effectiveness. The test aims to overcome some limitations of currently available screening methods, such as mammography and ultrasound, by offering greater safety and comfort, higher accessibility, lower cost, and exceptional quality. The target sensitivity (>93%) and specificity (>95%) are expected to surpass those of mammography (sensitivity 75–95%, specificity 80–95%).

The remaining significant terms of the agreement, including conditions for project execution, principles and procedures for disbursing funds, as well as conditions for suspending disbursements, ceasing financing, or terminating the agreement, do not deviate from standard terms commonly applied in such contracts.